Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. [electronic resource]
Producer: 20110111Description: 1701-8 p. digitalISSN:- 1558-3597
- Angiotensin II Type 1 Receptor Blockers -- administration & dosage
- Angiotensin-Converting Enzyme Inhibitors -- administration & dosage
- Benzimidazoles -- administration & dosage
- Benzoates -- administration & dosage
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Heart Failure -- epidemiology
- Humans
- Italy -- epidemiology
- Length of Stay
- Male
- Middle Aged
- Morbidity -- trends
- Prospective Studies
- Renal Dialysis -- methods
- Survival Rate -- trends
- Telmisartan
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.